

# Orphan GPCR Ligands

## EPPTB

A novel selective trace amine associated receptor 1 (TAAR1) antagonist ( $IC_{50}=28$  nM at mouse TAAR1). A useful tool for probing the physiologic role of TAAR1.<sup>1,2</sup>

**Product No: 10-1199** 5 mg 25 mg

## GW-9508

A selective agonist of the free fatty acid receptor, FFAR (GPR40 and GPR120).  $pEC_{50GPR40}=7.32$  and  $pEC_{50GPR120}=5.46$  in cells expressing GPR40 and GPR120.<sup>3</sup>

**Product No: 10-1108** 10 mg 50 mg

## GW1100

Selective antagonist at GPR40. Inhibits GPR40 agonist-mediated  $Ca^{2+}$  increases ( $pIC_{50}= 5.99$  for either agonist).<sup>3</sup> Blocks GPR40-mediated activation of insulin secretion.

**Product No: 10-4516** 5 mg 25 mg

## ISX9

Agonist at GPR68, an extracellular proton/pH-sensing GPCR. Enhances post-MI ventricular function in mice making GPR68 a therapeutic target for ischemic heart disease.<sup>4</sup>

**Product No: 10-1357** 5 mg 25 mg

## IPBT-5CA

A highly selective agonist at GPR109b ( $EC_{50}=400$  nM). No activity was reported at the highly homologous high affinity niacin receptor GPR109a.<sup>5</sup>

**Product No: 10-1070** 10 mg 50 mg

## NA-Gly

Endogenous endocannabinoid-like lipid which is a full agonist at GPR18.<sup>6,7</sup>

**Product No: 10-1200** 10 mg 50 mg

## Palmitoylethanolamide

Endogenous endocannabinoid-like lipid which is a selective GPR55 agonist ( $EC_{50}=4$  nM).<sup>8</sup>

**Product No: 10-1297** 20 mg 100 mg

## Tamoxifen citrate

Potent agonist at GPR30 (mammalian estrogen receptor).<sup>9</sup>

**Product No: 10-1256** 100 mg 1 g

## Synaptamide

Endogenous endocannabinoid-like lipid agonist at GPR110.<sup>10</sup>

**Product No: 10-1194** 5 mg 25 mg

## DC260126

Antagonist at GPR40.<sup>11</sup>

**Product No: 10-1531** 5 mg 25 mg

## AH-7614

Antagonist at GPR120.<sup>12</sup>

**Product No: 10-1521** 5 mg 25 mg

## PSB-KK1445


Potent and highly selective GPR18 agonist.<sup>13</sup>

**Product No: 10-4918** 5 mg 25 mg


## OX04528

Very potent, selective (inactive at GPR40, GPR120, and CB2), and orally bioavailable GPR84 agonist with no detectable effects on  $\beta$ -arrestin recruitment.<sup>14</sup>

**Product No: 10-4285** 5 mg 25 mg



EPPTB



GW-1100

## REFERENCES

1. Bradaia *et al.* (2009) Proc.Natl.Acad.Sci USA **106** 20081
2. Stalder *et al.* (2011) Bioorg.Med.Chem. Lett. **21** 1227
3. Brisco *et al.* (2006) Br. J. Pharmacol., **148** 619
4. Russell *et al.* (2012) ACS Chem.Biol. **7** 1077
5. Semple *et al.* (2006) J.Med.Chem. **49** 1227
6. McHugh *et al.* (2012) Br.J.Pharmacol. **165** 2414
7. McHugh *et al.* (2012) J.Mol.Signal. **7** 10
8. Ryberg *et al.* (2007) Br.J.Pharmacol. **152** 1092
9. Thomas *et al.* (2006) Endocrinology **146** 624
10. Lee *et al.* (2016) Nature Commun. **7** 13123
11. Zhang *et al.* (2010) *Biomed. Pharmacother.* **64** 647
12. Sparks *et al.* (2014) *Bioorg. Med. Chem. Lett.* **24** 3100
13. Mahardhika *et al.* (2024) J. Med. Chem. **67** 9896
14. Wang *et al.* (2024) J. Med. Chem. **67** 110